CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.

ABSTRACT: Cancer immunotherapy has gained attention as the supreme therapeutic modality for the treatment of various malignancies. Adoptive T-cell therapy (ACT) is one of the most distinctive modalities of this therapeutic approach, which seeks to harness the potential of combating cancer cells by using autologous or allogenic tumor-specific T-cells. However, a plethora of circumstances must be optimized to produce functional, durable, and efficient T-cells. Recently, the potential of ACT has been further realized by the introduction of novel gene-editing platforms such as the CRISPR/Cas9 system; this technique has been utilized to create T-cells furnished with recombinant T-cell receptor (TCR) or chimeric antigen receptor (CAR) that have precise tumor antigen recognition, minimal side effects and t

SUBMITTER: Ghaffari S 

PROVIDER: S-EPMC8390258 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature